RxDoctor Payments Data

Griselda Cheng-Akwa

Family · Lexington, KYNPI 1417412065

Payments from drug & device makers

$3,687in general payments, 2019–2025

Across 141 payments — averaging $26.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$726
  • Axonics, Inc.$695
  • Astellas Pharma US Inc$340
  • Progenics Pharmaceuticals, Inc.$220
  • Takeda Pharmaceuticals U.S.A., Inc.$169
  • Ferring Pharmaceuticals Inc.$164
  • plus $1K from 26 others

What the payments were for

  • Travel & lodging$3479%
  • Food & beverage$3,16486%
  • Education$1765%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,687 in reported general payments places this provider in the 85th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$61,079
Medicare patients
301
Services billed
1,427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron196$118,350
GemtesaVibegron166$95,589
LinzessLinaclotide37$19,778
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst294$7,392
Mirabegron ErMirabegron13$7,284
Tamsulosin Hcl741$4,593
Finasteride434$4,175
Trimethoprim62$2,838
Estradiol41$1,977
Oxybutynin Chloride ErOxybutynin Chloride91$1,480
Tadalafil11$1,422
Ondansetron Hcl166$1,201
Cefdinir109$1,100
Clobetasol Propionate24$648
Fluconazole142$500

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$340$118,350196 claims
Sumitomo Pharma America, Inc.Gemtesa$152$95,589166 claims
AbbVieLinzess$40$19,77837 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,374 family providers in Kentucky.

Other family in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →